Implication of Monoclonal Antibody for COVID-19 Treatment

Authors

  • Reshma Tuladhar Central Department of Microbiology, Tribhuvan University, Kathmandu

DOI:

https://doi.org/10.3126/jist.v25i2.33750

Keywords:

Immunotherapy, Monoclonal antibody, PRISMA, SARS-CoV-2, Tocilizumab

Abstract

Coronavirus induced disease-19 (COVID-19) pandemic affecting the entire world has continued to pose threat despite nearly a year of its onset. With more than 50 vaccine candidates targeting COVID-19 on trials and 15 at the final stage of testing, wide availability to the general public is still a long way to go. Thus alternative therapeutics is in the progress to minimize the effect of COVID-19. This systematic review evaluated the articles related to immunotherapy for COVID19. PubMed database was used to search for keywords; COVID-19, immunotherapy, and monoclonal antibody for relevant publications of the year 2020. The review was performed based on PRISMA protocol and the final 20 articles were included in the final review. These studies demonstrated that Tocilizumab, the monoclonal antibody that blocks IL6 receptors has improved outcomes in COVID-19 infected patients.

Downloads

Download data is not yet available.
Abstract
413
pdf
420

Downloads

Published

2020-12-25

How to Cite

Tuladhar, R. (2020). Implication of Monoclonal Antibody for COVID-19 Treatment. Journal of Institute of Science and Technology, 25(2), 133–140. https://doi.org/10.3126/jist.v25i2.33750

Issue

Vol. 25 No. 2 (2020)

Section

Review Articles

License

The views and interpretations in this journal are those of the author(s). They are not attributable to the Institute of Science and Technology, T.U. and do not imply the expression of any opinion concerning the legal status of any country, territory, city, area of its authorities, or concerning the delimitation of its frontiers of boundaries.

The copyright of the articles is held by the Institute of Science and Technology, T.U.